2020
A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).
Khan S, Zhao F, Solin L, Goldstein L, Cella D, Basik M, Golshan M, Julian T, Pockaj B, Lee C, Razaq W, Sparano J, Babiera G, Dy I, Jain S, Silverman P, Fisher C, Tevaarwerk A, Wagner L, Sledge G. A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108). Journal Of Clinical Oncology 2020, 38: lba2-lba2. DOI: 10.1200/jco.2020.38.18_suppl.lba2.Peer-Reviewed Original ResearchOptimal systemic therapyIntact primary tumorEarly local therapyLocoregional treatmentRecurrence/progressionOverall survivalSystemic therapyLocal therapyBreast cancerDe novo stage IV breast cancerDe novo metastatic breast cancerFACT-B Trial Outcome IndexNovo metastatic breast cancerRandomized phase III trialStage IV breast cancerCox proportional hazards modelInitial systemic therapyLocal disease progressionLocoregional disease controlMonths post randomizationYear OS ratesStage IV diseaseStage IV patientsPhase 3 trialPhase III trials
2008
Matched Pair Analyses of Stage IV Breast Cancer with or Without Resection of Primary Breast Site
Cady B, Nathan N, Michaelson J, Golshan M, Smith B. Matched Pair Analyses of Stage IV Breast Cancer with or Without Resection of Primary Breast Site. Annals Of Surgical Oncology 2008, 15: 3384-3395. PMID: 18726129, DOI: 10.1245/s10434-008-0085-x.Peer-Reviewed Original ResearchConceptsPrimary site surgeryBreast cancer patientsMatched-pair analysisIV patientsCancer resectionBreast surgeryCancer patientsSurvival advantageStage IVSite surgeryStage IV breast cancer patientsStage IV breast cancerExcellent responseApparent survival benefitBreast cancer resectionPrimary cancer resectionStage IV patientsStage III patientsSelection biasApparent survival advantageMatched pair analysisOligo metastasisInitial chemotherapyChart reviewSurvival benefit